The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making.
Biognosys turned proteomics into a true discovery technology with unprecedented precision, depth, and scale. Our industry-leading proteome coverage and high-throughput facility enable simultaneous quantification of thousands of proteins across thousands of samples. Through our proprietary technology and advanced data analytics capabilities we generate actionable insights for R&D and clinical research.
Biognosys is the world leader in next-generation proteomics contract research services to support pharma and biotech research and clinical development.
We offer a complete suite of software solutions for any mass spectrometry proteomics application in industry or academic life sciences research.
Our kits and reagents for sample preparation, quantification and quality control empower researchers to apply cutting-edge proteomics in-house.
The Agreement Aims to Accelerate the Continuum of Diagnostic Biomarker Discovery through to Assay Development and Clinical[...]READ MORE
What is large-scale discovery proteomics? Proteomics has the potential to bring about transformative changes in our understanding of biology and the therapeutic targets linked[...]READ MORE
At this year’s AACR Virtual Annual Meeting, Biognosys is proud to present a minisymposium, highlighting our work with AstraZeneca and ETH Zurich on the use of a novel[...]READ MORE
Through this development, Biognosys continues to advance industry standards for specificity and depth in[...]READ MORE
Advances in data science enable proteome data at a large-scale to be combined with other biodata and electronic patient health records, generating revolutionary novel insights for[...]READ MORE
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today the appointment of Karel Novy, PhD as Chief Operating[...]READ MORE